Literature DB >> 24903042

[Pain therapy in irritable bowel syndrome].

M de Greck1, P Layer, V Andresen.   

Abstract

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal diseases. It is characterized by chronic abdominal pain, typically associated with altered bowel habits that cannot be explained by structural abnormalities in routine diagnostic workup. Based on the predominant symptom, IBS can be divided into different subtypes: IBS with predominant constipation, diarrhea, bloating, or pain. Knowledge about the complex and multifactorial IBS pathophysiology has increased tremendously in recent years, e.g., IBS may be related to alterations in gastrointestinal motility, visceral sensitivity, and the mucosal immune system. It is important, both for the patient and the physician, that IBS diagnosis is made quickly and thoroughly based on the typical symptom complex and exclusion of relevant differential diagnoses and to reassure the patient that IBS is a chronic, but benign disease. These components are the fundamental basis for a good patient-physician relationship and for a successful long-term management of this potentially very compromising disorder. IBS therapy is based on general measures as well as symptom-oriented medical therapy, where improvement of abdominal pain is one of the main goals in treating IBS patients. Several pain treatment options are available, which may be used long-term or on demand and which may be combined with other therapies. General medical approaches include antispasmodics, improvement of bowel function, phytotherapy, and probiotics. Especially in patients with psychological comorbidities, antidepressants may be used. Modern drug treatments include the GC-C agonist linaclotide in IBS with predominant constipation, the locally acting antibiotic rifaximin in IBS with bloating, and 5-HT3 antagonists in IBS with predominant diarrhea. Psychotherapy should be included in an interdisciplinary approach in refractory cases or in psychological comorbidity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24903042     DOI: 10.1007/s00482-014-1406-6

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  30 in total

Review 1.  Herbal medicines for treatment of irritable bowel syndrome.

Authors:  J P Liu; M Yang; Y X Liu; M L Wei; S Grimsgaard
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

2.  [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management].

Authors:  P Layer; V Andresen; C Pehl; H Allescher; S C Bischoff; M Classen; P Enck; T Frieling; S Haag; G Holtmann; M Karaus; S Kathemann; J Keller; R Kuhlbusch-Zicklam; W Kruis; J Langhorst; H Matthes; H Mönnikes; S Müller-Lissner; F Musial; B Otto; C Rosenberger; M Schemann; I van der Voort; K Dathe; J C Preiss
Journal:  Z Gastroenterol       Date:  2011-02-01       Impact factor: 2.000

3.  Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention.

Authors:  H Mertz; V Morgan; G Tanner; D Pickens; R Price; Y Shyr; R Kessler
Journal:  Gastroenterology       Date:  2000-05       Impact factor: 22.682

4.  Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome.

Authors:  Michael Camilleri; Sanna McKinzie; Irene Busciglio; Phillip A Low; Seth Sweetser; Duane Burton; Kari Baxter; Michael Ryks; Alan R Zinsmeister
Journal:  Clin Gastroenterol Hepatol       Date:  2008-05-05       Impact factor: 11.382

Review 5.  Hypnotherapy for treatment of irritable bowel syndrome.

Authors:  A N Webb; R H Kukuruzovic; A G Catto-Smith; S M Sawyer
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

6.  Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.

Authors:  E M M Quigley; J Tack; W D Chey; S S Rao; J Fortea; M Falques; C Diaz; S J Shiff; M G Currie; J M Johnston
Journal:  Aliment Pharmacol Ther       Date:  2012-11-01       Impact factor: 8.171

Review 7.  Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Viola Andresen; Victor M Montori; Jutta Keller; Colin P West; Peter Layer; Michael Camilleri
Journal:  Clin Gastroenterol Hepatol       Date:  2008-01-31       Impact factor: 11.382

8.  Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.

Authors:  Elizabeth J Videlock; Vivian Cheng; Filippo Cremonini
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-02       Impact factor: 11.382

Review 9.  Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.

Authors:  A C Ford; N J Talley; P S Schoenfeld; E M M Quigley; P Moayyedi
Journal:  Gut       Date:  2008-11-10       Impact factor: 23.059

10.  Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers.

Authors:  Lotta Krogius-Kurikka; Anna Lyra; Erja Malinen; Johannes Aarnikunnas; Jarno Tuimala; Lars Paulin; Harri Mäkivuokko; Kajsa Kajander; Airi Palva
Journal:  BMC Gastroenterol       Date:  2009-12-17       Impact factor: 3.067

View more
  1 in total

Review 1.  [Visceral pain].

Authors:  S Elsenbruch; W Häuser; W Jänig
Journal:  Schmerz       Date:  2015-10       Impact factor: 1.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.